Physician profile
Michael D Sims
NPI 1427053180
$8,844.78
in general payments reported to CMS, 2019-2025
50 companies · $1,453 in 2025
The $1,453 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,565 · 2022: $2,075 · 2023: $2,184 · 2024: $1,567 · 2025: $1,453.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,204.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,080.14 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $948.90 | 2021-2025 | Trelegy Ellipta |
| Abbvie INC. | $890.47 | 2021-2025 | |
| Pfizer INC. | $790.80 | 2021-2025 | |
| Lilly USA, LLC | $607.80 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $585.55 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $468.10 | 2021-2024 | Jardiance, Synjardy, Tradjenta |
| Merck Sharp & Dohme LLC | $384.12 | 2021-2025 | Belsomra, Gardasil 9, Steglatro |
| Amgen INC. | $324.16 | 2021-2025 | Otezla, Repatha, Otezla |
| Novartis Pharmaceuticals Corporation | $314.81 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $211.97 | 2021-2024 | Ajovy, Austedo Xr, Austedo |
| Corcept Therapeutics | $147.53 | 2024-2025 | Korlym |
| Otsuka America Pharmaceutical, INC. | $137.42 | 2021-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $135.40 | 2021-2025 | |
| Amarin Pharma, INC. | $123.48 | 2021-2022 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Sims listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.